Financially Bloated American Cancer Society Fails to Prevent Cancer
April 30, 2010
Title
American Cancer Society: The World’s Wealthiest “Non-profit” Institution
Source International Journal of Health Services, Volume 29, number 3, 1999
Author Samuel S. Epstein
Faculty Evaluator Cindy Stearns Ph.D.
Student Researcher Jennifer Acio-Peters & Lisa Desmond
The American Cancer Society (ACS) is growing increasingly wealthy, thanks to donations from the public and funding from surgeons, drug companies, and corporations that profit from cancer cures. More than half the funds raised by the ACS go for overhead, salaries, and fringe
benefits for its executives and other employees, while most direct community services are handled by unpaid volunteers. The value of cash reserves and real estate totals over $1 billion, yet only 16 percent of funds go into direct services for cancer victims. Conflicts of interest affect ACS’s approach to cancer prevention. With a philosophy that emphasizes faulty lifestyles rather than environmental hazards, the ACS has refused to provide scientific testimony needed for the regulation of occupational and environmental carcinogens. The Board of Trustees includes corporate executives from pharmaceutical industries with a vested interest in the manufacture of both environmental carcinogens and anti-cancer drugs.
Coverage 2000
The American Cancer Society continues to conduct business as usual with little mainstream media coverage of its activities. There are a few notable exceptions.
The United Way of Los Angeles has changed its approach toward charitable donations, resulting in the ACS regional office standing to lose about $700,000 in United Way funding. Needless to say, it opposes the fundraiser’s decision. Whether the United Way can adhere to its new policy or must capitulate to the demands of large national institutions like the ACS remains to be seen.
The Ohio Division of the ACS made local and regional news when its
chief administrative officer was accused of embezzling nearly half the organization’s $15 million annual budget. Daniel Stephen Wiant wired $6,936,250 from an ACS
account to an investment banker in Kufstein, Austria, and then promptly left the country. The ACS Ohio Division was unaware the money was gone until six days later when notified by the FBI. The incident underscores the lax financial control within the organization. As the Columbus Dispatch commented, “[T]he claim by one society official that the organization has ‘superlative’ financial controls is simply unbelievable.” Wiant had a recent criminal record spanning 10 years including convictions in Hawaii, California, and Ohio. The ACS started doing
background checks on its employees since Wiant’s hire, especially of those, like Wiant, who are put in charge of finances. Curiously, this incident followed an earlier embezzlement of $150,000 by another individual.
The Dispatch raised the issue of general ACS credibility, referring to a May 1998 survey that showed that while 96 percent of Americans recognize the organization by name, only 5 percent know what it does with its money. In his book, Unhealthy Charities, Thomas DiLorenzo points out that $140 million of the $556 million the ACS raised in 1998 went to administrative and advertising costs.
Information regarding ACS revenues and compensation for high level officials also found its way into print in 2000. A National Journal article listed the American Cancer Society’s 1998 Internal Revenue filings. According to the IRS, the ACS had revenues totaling $241,577,836. The CEO at the time, John R. Seffrin, received a $325,000 salary along with $94,571 in benefits and allowances.
Incidentally, President Clinton’s fiscal year 2001 budget is reported to include an unprecedented funding increase to explore the environmental causes of diseases like breast and prostate cancer. Undoubtedly, some of these funds will find their way to the American Cancer Society. Along the way, the investment practices of charitable foundations in general came under scrutiny. The Bill and Melinda Gates Foundation, the largest charitable foundation with a $22 billion endowment, spends much of its money on efforts to help “improve people’s lives through health and learning.” However, the New York Times discovered that while it supports charities like Cancer Lifeline and ACS, it also owns bonds in the Philip Morris tobacco company.
Tamoxifen, championed by ACS, reappeared in the news. AstraZeneca’s product remains controversial and has been challenged by reportedly more effective drugs, according to the San Antonio Breast Cancer Symposium. The symposium took place in late 1999, yet tamoxifen is still widely used. Despite new information, the Food and Drug Administration (FDA) is still conducting research on the drug.
The FDA has had its own problems with AstraZeneca this past year. In August, they had to caution the makers of tamoxifen against publishing misleading information in journal ads and promotional brochures, which suggesting that their drug was more effective than studies had actually demonstrated. They also understated its side effects. Such advertisements had appeared in journals targeting obstetricians, gynecologists, and other doctors who care for women.
Sources: PR Newswire, December 10, 1999, & March 14, 2000; The National Journal, Inc., January 15, 2000; The Los Angeles Times, January 20, 2000; International Journal of Health Service, Volume 30, Number 2, 2000, “Legislative Proposals for Reversing the Cancer Epidemic and Controlling Run-Away Industrial Technologies, by Samuel S. Epstein; The Plain Dealer, June 8, June 19, & August 24, 2000; The Columbus Dispatch, June 11, & July 8, 2000; The New York Times, June 11, 2000, “Charities’ investing: Left Hand, Meet Right,” by Reed Abelson; USA Today, August 8, 2000.
2000 Update by author Samuel S. Epstein
The American Cancer Society Threatens the National Cancer Program
Operating behind closed doors and with powerful political connections, the American Cancer Society (ACS) is charged with forging a questionable and possibly illegal alliance with the federal Centers for Disease Control and Prevention (CDC) in attempts to hijack the National Cancer Program. The background to the ACS political agenda reveals a pattern of self-interest, conflicts of interest, lack of accountability, and non-transparency, to which the media have responded with deafening silence.
President Nixon’s 1971 National Cancer Act, mandating the National Cancer Program directed by the National Cancer Institute (NCI), is under powerful attack by the ACS, the world’s largest non-religious charity. The ACS is lobbying to replace the 1971 Act by new legislation, assigning responsibility to and requiring coordination between the private sector, patient advocacy groups, and the public sector, the NCI, and CDC. Of major concern are the highly questionable close CDC-ACS relationship and efforts to divert emphasis and funds away from NCI’s peer-reviewed scientific research to CDC’s state and community public health programs primarily focused on screening and behavioral intervention.
The September 26, 1998, “March: Coming Together to Conquer Cancer,” brought several advocacy groups representing 125,000 survivors to Washington, DC. However, it failed to create a community of scientists and patients unified by a common political agenda, and even strained their willingness to collaborate. The ACS was a minor and reluctant player in the march, recognizing that breast, prostate, and other advocacy groups posed a growing threat to its fundraising. However, the ACS deftly used the march to capture its PR fallout by creating the National Dialogue on Cancer (NDC), a purportedly independent forum co-chaired by former President George Bush and Barbara Bush, vice-chaired by Senator Dianne Feinstein (D-CA), and including Governors Tom Ridge of Pennsylvania and Tommy Thompson of Wisconsin. The NDC activities are managed by a 16-member steering committee, with representation from ACS, CDC, NCI, cancer survivors, the underserved, and the pharmaceutical industry, which meets behind closed doors; NCI’s involvement has been nominal, at best.
In turn, the NDC leadership selected a group of more than 100 collaborating partners, including representatives of major advocacy groups, some of whom declined the invitation, while others failed to attend meetings or frankly suspected their agenda as a thinly disguised vehicle for furthering ACS special interests. On August 8, 1999, the NDC shocked its collaborating partners by suddenly announcing the formation of a National Cancer Legislation Advisory Committee to advise Senator Feinstein on rewriting the National Cancer Act. This 25-member committee was co-chaired by Dr. John Seffrin, CEO of the ACS, and Dr. Vincent DeVita, Director of the Yale Cancer Center and former NCI director, without any participation by the Steering Committee and NDC’s collaborating partners. Apart from NDC’s high-handed conduct and supposedly independent legislation committee spinoff, there are major concerns on interlocking ACS-CDC interests. CDC has improperly and possibly illegally funded ACS with close to $3 million for a sole source four-year cooperative agreement, and also the NDC with $100,000. In turn, ACS has made strong efforts to upgrade CDC’s role in the National Cancer Program, and also to increase appropriations for its non-peer reviewed cancer programs.
The relationship between the ACS, NDC, and the Legislation Committee raises fundamental questions on conflicts of interest. As reported in The Cancer Letter, a Washington, DC, newsletter widely read within the cancer establishment, John Durant, former executive president of the American Society for Clinical Oncology, charged: “It has always seemed to me that this was an issue of control by the ACS over the cancer agenda.…They are protecting their own fundraising capacity…against competition by advocacy groups.” More seriously, the leading U.S. charity watchdog, The Chronicle of Philanthropy, concluded: “The ACS is more interested in accumulating wealth than saving lives.”
DeVita, the legislation committee co-chair, is also chairman of the Medical Advisory Board of CancerSource.com, a website launched by Jones & Bartlett (Sudbury, MA) that publishes the ACS “Consumers Guide to Cancer Drugs”; three members of the legislation committee also serve on the same board. Thus, DeVita appears to be developing his personal interests in a publicly-funded forum. The ACS priority for tobacco cessation programs is inconsistent with its industry relationships. According to The Cancer Letter, Shandwick International, via its Division Management subsidiary, which represents R.J. Reynolds, has been a major PR firm for the NDC and Legislation Committee. Also, Edelman PR, representing Brown & Williamson Tobacco Company, which handles publicity for Team KOOL Green championship auto racing, was hired by ACS to conduct voter education programs aimed at making cancer a major issue in the 2000 presidential campaign. Further improprieties relate to questionably legal ACS contributions to Democratic and Republican governors associations. “We wanted to look like players and be players,” ACS explained.
More disturbing is ACS’s three-decade track record of indifference and even hostility to cancer prevention. Examples include issuing a joint statement with the Chlorine Institute justifying the continued global use of persistent organochlorine pesticides, and also supporting the industry in trivializing dietary pesticide residues as avoidable risks of childhood cancer. ACS policies are further exemplified by its allocation of less than 0.1 percent of its $700 million annual budget to environmental and occupational causes of cancer.
In this connection, there are also growing and urgent concerns with regard to the NCI’s imbalanced preoccupation with basic research, besides damage control-screening, diagnosis and treatment-with minimal priorities and budgetary allocations for mission research on primary prevention and public outreach on avoidable causes of cancer. ACS, with its NDC and legislation spinoffs, has disqualified itself from any leadership role in the National Cancer Program. The public should be encouraged to redirect its funding away from the ACS to patient and prevention advocacy groups. The conduct of ACS, particularly its political lobbying and possibly illegal relationship to CDC, should be investigated by the House and Senate appropriations and oversight committees. Finally, Congress should ensure that the National Cancer Program directs the highest priority to cancer prevention.
2000 Update by Barbara Seaman, Project Censored National Judge
Dr. Samuel Epstein’s thoroughly documented exposé of pervasive conflicts of interest in the “cancer establishment,” particularly the American Cancer Society (ACS), has already demonstrated a measurable impact. A major step toward full disclosure, which could lead to the reduction of female cancers, was taken on December 15, 2000, when a blue-ribbon government panel-the NIH’s National Toxicology Advisory Committee-voted 8-1 to add prescription estrogens to the official list of “known carcinogens.”
The ACS, along with much of the OB/Gyn establishment, has been so thoroughly influenced, lulled, perhaps even “brainwashed” by the prescription drug industry that 60 years-during which the frequency of hormone dependent female cancers has more than doubled in the United States-elapsed before the official labeling of steroid estrogens as carcinogens could be openly acknowledged. There was no suggestion that estrogen use be restricted or banned, but at meetings of the Toxicology Advisory Committee some scientists did express hope that prescribing physicians might become more cautionary. Toxicologist Michelle Medinsky stated, “They only discuss benefits. Listing might force it on the table…. Is knowledge power or is ignorance bliss? Everyone has to make their own decision.”
My concerned colleagues and I have difficulty understanding why so many well-intentioned environmental cancer-prevention activists often fail to identify the estrogen products themselves in their research radar. Winning pieces on cancer factors in the environment that looked for estrogenic chemicals, phyto estrogens, xeno estrogens, and so on, seemed oblivious to the fact that prescription and veterinary estrogens should be placed in square one. It seems like a waste of research money to examine these other factors without looking simultaneously at exposure to prescription and (in so far as possible) veterinary estrogens in the same populations. To give one example, breast cancer activists on New York State’s Long Island have investigated possible environmental causes of atypically high rates without also including questions on exposure to diethelstilbestrol (DES). In the post-World War II era, Long Island was one of the major “hotbeds” of routine DES-prescribing to pregnant women, based on the unjustified belief that it prevented miscarriages. This practice ended abruptly in 1971, when some of the daughters exposed in utero were diagnosed with reproductive tract abnormalities, particularly vaginal adenocarcinoma, which is often lethal. By 1978, when I served on the U.S. Surgeon General’s task force on DES, an increased frequency of breast cancer in the DES-exposed mothers was also recognized. Twenty-three years later, in 2001, this finding was reconfirmed in the British Medical Journal, Volume 84, Number 1.
“Estrogen Sea”
“Veterinary” estrogens may be incurred through vocational exposure in laboratories and feedlots or through dangerously high dietary consumption of estrogen-fed meat and poultry. But further, most commercial estrogen products are not biodegradable by the stomach acids, and therefore residues are normally excreted in urine. Some eminent European scientists have posited in the Lancet that excreted estrogens in the food chain and water (supplied in the United States not only by women on prescription drugs, but by livestock as well) may have us “swimming in a sea of estrogens.” This, the theory goes, would account for the lockstep rise in certain male cancers, and infertility in some aquatic creatures, along with the rise in female cancers.
In fact, the carcinogenicity of synthetic estrogens in laboratory animals that have similar patterns to humans was established in historic experiments performed by Michael B. Shimkin and Hugh C. Grady, and published in the Journal of the National Cancer Institute in 1940. In December 1947, less than a decade after estrogen products for treating menopause first came on the market, the Journal Of Obstetrics and Gynecology published Dr. Saul Gusberg’s report on 29 cases of cancers and pre-cancers of the uterus associated with such therapy. By 1971, as mentioned, Dr. Arthur Herbst confirmed the tragic outcome of DES estrogens in pregnancy. In 1975 the FDA commissioner sent emergency notification to all U.S. physicians that four separate studies had confirmed a four- to eightfold increase in uterine cancer in long-term users of estrogens for menopause.
By the 1990s it was demonstrated that adding progestin to the estrogen regimen gives considerable protection against uterine cancer, but, at the same time, raises the patient’s risk of breast cancer to three times greater than taking estrogens alone. The longer a woman stays on hormones, the more her chances of uterine and breast cancer keep rising. If you have a uterus and take estrogens without progestins, you invite cancer of the uterine lining. If you add progestins to the estrogen you avoid the cancer “down there,” but substantially increase your chances of getting it “up front” in your breast.
“Keep Heron Premarin”
The major hormone-product manufacturers, including Ortho (Johnson and Johnson) and Wyeth Ayerst, are vigilant in censoring journalists and physicians who criticize or question their products. Hormone drugs are extraordinary sources of income simply because (unlike drugs for the sick) so many healthy women stay on them indefinitely. (For example, 12 million menopausal and postmenopausal U.S. women take estrogen alone, while 8.6 million take it in combination with progestin. Perhaps another 10 million to 14 million take the birth-control pill.) Ortho is the world’s largest manufacturer of oral contraceptives; while Wyeth-Ayerst’s Premarin (which stands for PREgnant MARes urINe) is the only prescription drug to remain in the top 50 bestsellers for more than half a century, and remained number one in 1999.
I am used to having Ortho and Wyeth Ayerst withdraw their ads from magazines to which I contribute, and their funds from medical conferences that include me on their programs. Indeed, when asked to speak at an event that may have industry sponsorship, I often warn the inviters thatthey may have to cancel me. Industry blacklists have become commonplace, extending to physicians and scientists, as well as journalists, who are deemed “unfriendly.” But what I never expected was that Wyeth Ayerst would succeed in blackballing me at my own journalism school, Columbia University, where I was a Sloan Rockefeller Advanced Science Writing Fellow in 1967-68, the year that I began The Doctors’ Case Against the Pill, the very book that first brought the hormone industry’s wrath down upon me.
By the 1990s Kenneth Goldstein, then teaching the science writing courses, was accepting funds from Wyeth Ayerst for student junkets, sending them to cover pro-estrogen conferences, which they were expected to write up for a Wyeth-Ayerst puff publication on menopause. One student became disturbed about the assignment and contacted me for advice. From the moment I confronted Goldstein, I was repeatedly excluded from speaking at any and all journalism-school panels or forums on medical or population issues. Kenneth Goldstein retired recently, and I am waiting to see whether or not I am to be resuscitated.
A period of public comment follows additions to our federal lists of carcinogens. Manufacturers of hormone products, as well as some doctors who heavily prescribe them will, if true to form, object to this classification and try to have it modified. I hope that Project Censored readers who value full disclosure and informed consent will write to the NIH in support of the Toxicology Advisory Committee’s long- overdue move. Comments on estrogens (supporting or opposing) can be sent to: National Institute of Environmental Health Sciences/National Toxicology Program (NIEHS/NTP), Dr. C.W. Jameson, EC-14, P.O. Box 12233, Research Triangle Park, N.C. 27709. Copies may be sent to Barbara Seaman, c/o Project Censored, Seven Stories Press, 140 Watts Street, New York, NY 10013. The exact language of the recommendation can be viewed in The Federal Register.
Cannabis and Cancer
JEREMY KOSSEN
February 27, 2016
This is part one of a two-part series. Part two examines the evidence thatcannabis can cure cancer.
Cancer has touched the lives of nearly every American, either directly or through a loved one. Although the US Food & Drug Administration hasn’t approved marijuana as a cancer treatment, America’s shifting legal landscape has encouraged many patients to consult their
physicians about the effects it can have on
cancer and cancer-related symptoms.
The medical benefits of cannabis are no secret. In October 2003, the government patented medical marijuana under
US Patent # 6630507, which mentions the antioxidant properties of
cannabinoids. The patent also identifies the active chemicals in cannabis that cause drug-like effects on the body, and cites their benefits for patients going through chemo, radiation, or other sources of oxidative stress.
What is Cancer?
Cancer is not one disease, but the name given to a collection of related diseases characterized by an abnormal growth of cells. There are more than 100 different types of cancer that are caused by both external factors (such as smoking, viruses, or carcinogens) and genetic factors (such as genetic mutation inherited from one’s parents). Trillions of cells compose the human body, meaning cancer could start anywhere.
Like humans, cells grow old or become damaged and eventually die. Other cells grow and divide to form new ones to replace these old and damaged cells, but when cancer develops, abnormal cells including the old and damaged ones survive even though they should die. Some of the body’s cells will start to divide interminably and spread into surrounding tissues, creating new cancerous cells that aren’t needed. And since these new cells won’t stop growing and dividing, they are likely to hide in the immune system and form abnormal growths like masses of tissue known as tumors.
Cancerous tumors can spread into and invade nearby tissues because they’re malignant. Although they can be removed, these tumors are likely to grow back. As tumors grow, cancer cells can break off and travel through the blood or the lymph system to any other part of the body to form new tumors — often far away from the original one. This process is known as metastasis.
Benign tumors, on the other hand, don’t spread to or invade nearby tissue and won’t grow back after being removed. Unfortunately, benign tumors in the brain can be life-threatening.
What are the Symptoms of Cancer?
Cancer (and its treatments) leave its host feeling weak and dizzy. Symptoms may differ depending on where in the body the cancer is located, but may include:
- Blood in pee or stools
- Bruising
- Changes in genitalia
- Coughs lasting more than a month or accompanied by blood
- Depression
- Difficulty breathing
- Difficult bowel movements
- Discomfort after eating
- Fever
- Fatigue
- Heartburn
- Lumps or swelling
- Persistent indigestion
- Night sweats
- Spots and growths on the skin or changes in size, shape, and color of an already-existing mole like yellowing, darkening, or redness
- Sores that won’t heal
- Weight loss
- Weight gain
- Unexplained bleeding
- Unexplained joint pain
What are Current Cancer Treatments?
Cancer treatment can be costly and time-consuming, often requiring repeat visits to administer treatments in cycles. Doctors will likely begin by performing a biopsy to determine which treatment will be most effective.
Surgery: Surgeries can be performed to remove or debulk tumors and ease the pains and pressure they’re causing. Tumors can sometimes be removed using minimally invasive surgery. Surgeons will often remove some healthy tissue and lymph nodes as well.
Radiation: High doses of radiation can kill cancer cells after weeks of treatment or slow their growth, as well as shrink tumors. Sadly, it can take months for the cancerous cells to die and radiation can leave patients feeling exhausted by killing or damaging healthy cells.
Chemotherapy: Chemo, which is the use of drugs to directly kill cancer cells, became one of the most common ways to treat cancer in the 1940s. It is often administered in cycles. Today, more than 100 drugs are used to treat cancer, while more are being investigated and developed.
Immunotherapy: Immunotherapy is the administration of living organisms to stimulate the immune response, which often leaves the patient with flu-like symptoms.
Hormones: Administered orally, via injection, or during surgery, hormone therapy can be used to stop or slow the growth of cancer cells and reduce or prevent cancer symptoms from arising. It can be used with other treatments to lessen the chance of the cancer returning. Along with nausea, diarrhea, and fatigue, hormone therapy may weaken bones and cause menstrual changes in women.
Heat: Local hyperthermia can destroy small areas of cells (like a tumor), while regional hyperthermia, or whole-body hyperthermia, can be used in conjunction with other treatments to help them work better. Hyperthermia may be created externally, using a machine’s high energy waves aimed at the tumor, or internally, when a thin needle is put right into the tumor to release heat energy.
How Can Cannabis Help Cancer?
Cannabis contains at least 85 different types of cannabinoids, the active chemicals that create drug-like effects throughout the body. The impact of these cannabinoids in treating cancer symptoms as well as the side effects of cancer therapies is so favorable, cannabinoids are synthesized for legal, prescription use. Dronabinol and Nabilone/Cesamet, two synthetic pill forms of THC, are FDA-approved and currently being used to treat
nausea and vomiting associated with chemo.
Cannabinoids that are known to benefit people living with cancer include CBC,
CBD, CBDa, CBG, THC, and THCa. Cannabidiol (CBD) is known to relieve pain, lower inflammation, and decrease anxiety without the “high” of THC, the primary psychoactive ingredient in cannabis. In Canada, a cannabis extract containing THC and CBD called Nabiximols/Sativex is approved for pain relief in patients with advanced cancer and multiple sclerosis.
According to the U.S. government’s National Cancer Institute, other effects of cannabinoids include anti-inflammatory activity, blocking cell growth, preventing the growth of blood vessels that supply tumors, fighting viruses, and relieving muscle spasms.
NCI also acknowledges that inhaled cannabis is attributed to improved mood and sense of well-being. Studies suggest cannabis can be used for symptom management in cancer patients by preventing vomiting, stimulating appetite, providing pain relief, and improving sleep as well as inhibiting the growth of certain types of tumors.
Other studies leading scientists down promising avenues of cancer treatment include:
- A 1996 study discovered the protective effects of cannabinoids on the development of certain types of tumors. Cannabinoids were observed causing cell death, blocking cell growth, and preventing the development of the blood vessels tumors needed to grow — suggesting cannabinoids may be able to kill cancer cells while protecting normal cells.
- A series of studies on brain tumors conducted in 2003 proved CBD may make chemo more effective and increase the deaths of cancer cells without harming normal cells.
- A 2004 study on mice which showed cannabinoids protect against inflammation of the colon, thus reducing the risk of colon cancer and possibly aiding in its treatment.
- In 2011, the American Association for Cancer Research revealed CBD kills cells associated with breast cancer while having little to no effect on normal breast cells. When studied in mice, CBD reduced the growth, number, and spread of tumors.
- The National Institute of Health published a study in 2011, Cell Death & Differentiation, that demonstrates THC and JWH-015 (a cannabinoid receptor), decreased the viability of liver cancer cells. Cannabinoids were also shown to inhibit tumor growth and the accumulation of fluid in the abdomen. These are significant findings as they may be helpful in the design of therapeutic strategies to manage liver cancer.
- A study published in February 2015 found rates of bladder cancer are 45% lower in cannabis users, compared to those who do not use it.
- According to the National Cancer Institute (NCI), preclinical studies demonstrate the efficacy of cannabinoids to inhibit tumor growth by protecting healthy cells while killing cancer cells and obstructing the growth of cells and blood vessels needed for tumors to grow. The NCI also claims that a lab study of THC killed or damaged cancer cells, and when the study was repeated in mouse models, showed it had anti-tumor effects that could aid in the fight against lung and breast cancer.
Cannabinoid receptors have been discovered in the brain, spinal cord, and nerve endings throughout the body, suggesting cannabis may play a larger role in immunity as well.
Several studies are in progress on the effects of cannabis on cancer in adults, including:
- Treating solid tumors with oral CBD
- Treating recurrent glioblastoma multiform with a THC/CBD oral spray
- Treating graft-versus-host disease with CBD in patients who’ve undergone stem cell transplants
Don’t miss part two of our Cannabis and Cancer series, where we look at
whether cannabis can cure cancer.
Can Cannabis Cure Cancer?
JEREMY KOSSEN
March 27, 2016
Given that
39.6% of Americans will be diagnosed with cancer at some point in their lives, cancers affects nearly everyone. Chances are, someone close to you has battled cancer.
Oncologists, more than doctors in any other discipline within medicine, support the option of recommending cannabis as part of a treatment program for patients suffering from cancer. However, while the positive effects of using cannabis to alleviate cancer symptoms have been well documented, the U.S. government continues to classify cannabis as a Schedule I drug — high potential for abuse and no known medical use. Consequently, the federal government’s position on cannabis stifles much-needed research on cannabis as a “cure” for cancer.

RELATED STORY
Government-Run Cancer Institute Quietly Acknowledges That Cannabis Kills Cancer Cells
Moreover, the federal government’s position has fueled massive misinformation about cannabis as a potential cure for cancer. On the one hand, the federal government officially claims cannabis has no medicinal value. On the other hand, many pseudoscience “cancer quacks” unethically exaggerate claims of cannabis as the ultimate cure for cancer providing unsubstantiated help to thousands of cancer patients.
So what is the truth?
What is a Cancer “Cure?”
On the question of cannabis as a cure, Dr. Abrams, a cannabis advocate and one of the leading oncologists and cancer researchers in the world, cautions on the use of the term “cure”:
“Cure is a huge word in oncology. It usually implies that the patient has survived 5 years without evidence of their cancer. We are able to cure more cancers today than we were when I began my career as an oncologist. That has been through advances in diagnosis and treatment with conventional therapies.”
As a cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion in San Francisco and an oncologist for more than three decades, Dr. Abrams observes:
“[After] 33 years of being an oncologist in San Francisco, I would guess that a large proportion of the patients I have treated have used cannabis. If cannabis definitively cured cancer, I would have expected that I would have a lot more survivors. That being said, what we do know is that cannabis is truly an amazing medicine for many cancer and treatment-related side effects — nausea, vomiting, loss of appetite, pain, depression, anxiety, insomnia.”
Dr. Abrams’ opinion reflects a consensus within the credible oncologist and cancer scientific community: there is no doubt that cannabis is effective at treating cancer-related symptoms and treatment-related side effects, but the jury is still out on whether cannabis can actually “cure” cancer.

RELATED STORY
What Are the Best Cannabis Strains for Cancer-Related Symptoms?
If It’s on the Web, It Must Be True, Right?
Because cancer affects so many people, it’s natural to want confirmation that cannabis can, without question, cure cancer. The Web is rich with stories from people who claim cannabis, particularly “cannabis oil,” cured or reversed their cancer. When we asked Dr. Abrams why he thought there are so many anecdotal claims of cannabis curing people’s’ cancer, he cautioned:
“I note that many of the people who are very vocal about how
cannabis oil cured their cancers seem to forget that they also received conventional therapies. If people really have used only cannabis oil and can truly document that they have cured their cancer (other than a skin cancer), they need to submit that data to the
National Cancer Institute’s Office on Cancer Complementary and Alternative Therapy’s
Best Case Scenario website so that evidence can be documented.”
Further, note that many of the numerous articles available that make declarative claims that cannabis cures cancer misrepresent studies, exaggerate claims, or omit key facts.

RELATED STORY
Explore the Diverse World of Cannabis Oil and Concentrates
Cannabis Cancer Research Shows Promise, But We Need to Do More
As we search for anti-cancer treatments, the anti-cancer potential of cannabis has been examined in numerous scientific studies on
cannabinoidreceptors and endocannabinoids, resulting in promising leads. Significant research has demonstrated that cannabinoids may inhibit or stop the growth of cancers — including breast, brain, liver, pheochromocytoma, melanoma, leukemia, and other kinds of cancer — from spreading or growing. Moreover,
cannabinoids have proven to promote apoptosis, the programmed death of tumor cells, while stopping angiogenesis, blood vessel production to the tumor. One study, conducted by Madrid’s Complutense University, showed that in one-third of rats treated, the injection of synthetic THC
eliminated malignant brain tumors while extending life in another third.

RELATED STORY
Cannabis and Cancer
The research is promising, but thus far it has been limited to preclinical studies, which are studies of drugs or treatments in animals prior to being carried out in humans. While the preclinical research offers hope, before anyone can confidently claim that cannabis can provide a “cure,” clinical research needs to be done.
Further, because cancer describes a group of diseases involving abnormal cell growth, it’s unlikely there will be a single “cure-all” cannabis remedy. Likewise, naturally-derived or synthetic cannabinoid agonists may be need to be combined with traditional chemotherapeutic regimens or supplemental alternative medicines.
In order for cannabis to find its way into routine clinical cancer treatment, rigorous pharmacological and clinical studies need to be done. And to accelerate this process, the federal government should
lift the federal ban on medical cannabis.

RELATED STORY
Cancer Sucks and Cannabis Can Help – If the Feds Would Let It
Paradoxically, the federally-funded National Cancer Institute has warmed up to cannabis as a cancer treatment and has even quietly acknowledged that
cannabis has been shown to kill cancer cells in preclinical studies. Nonetheless, the federal government has yet to make any significant strides to align their position with the scientific community and the overwhelming number of Americans.
With more and more states legalizing medical usage and the majority of Americans supporting medical cannabis, we can hope the federal government will finally modify its draconian prohibitory position and if indeed, cannabis can cure cancer, those suffering will no longer have to turn to questionable sources to learn how cannabis may help them.